Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Omalizumab

Brand: Xolair®
NICE TA: 339
Indication: Chronic spontaneous urticaria (NICE TA339)
Disease category: Skin
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Omalizumab is recommended as an option as add‑on therapy for treating severe chronic spontaneous urticaria in adults and young people aged 12 years and over only if:
• the severity of the condition is assessed objectively, for example, using a weekly urticaria activity score of 28 or more
• the person’s condition has not responded to standard treatment with H1‑antihistamines and leukotriene receptor antagonists
• omalizumab is stopped at or before the fourth dose if the condition has not responded
• omalizumab is stopped at the end of a course of treatment (6 doses) if the condition has responded, to establish whether the condition has gone into spontaneous remission, and is restarted only if the condition relapses
• omalizumab is administered under the management of a secondary care specialist in dermatology, immunology or allergy
• the company provides omalizumab with the discount agreed in the patient access scheme.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA339 - Omalizumab for previously treated chronic spontaneous urticaria

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red